1. Scrip

Chugai Building On Roche Alliance Success As It Eyes Future: CEO Okuda

Digital Strategy Now In Focus

 
• By Lisa Takagi

In an exclusive interview with Scrip, Chugai's CEO says the now 20-year-old strategic partnership with Roche has been one of the keys to Chugai’s successful growth and has allowed smooth market expansion for both firms, as well as enabling R&D investment by the Japanese firm. A flexible, platform-based approach to R&D, rather than focusing on specific target diseases or technologies, has also benefitted Chugai, Osamu Okuda noted.

Dr. Osamu Okuda, CEO of Chugai, explained Chugai's strategy behind its flexible R&D attitude.
CEO Osamu Okuda explains Chugai's flexible R&D strategy • Source: Lisa Takagi

For the past 20 years, major Japanese pharmaceutical firm Chugai Pharmaceutical Co., Ltd. has been a source of globally successful antibodies, including Hemlibra (emicizumab) for hemophilia and immunosuppressant Actemra (tocilizumab).

The global partnership with parent Roche Holding AG since 2002 has clearly helped the path to stable business growth, while allowing continuous investment into R&D and providing a path

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia